Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Court Pedersen

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
BMC Infectious Diseases|April 9, 2014
Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in EthiopiaAlemseged Abdissa, Daniel Yilma, Jannik Fonager, et al.
Plos One|June 2, 2012
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Åsa Alsiö, Karolina Rembeck, Galia Askarieh, et al.
Hepatology (Baltimore, Md.)|February 13, 2014
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3Karolina Rembeck, Jesper Waldenström, Kristoffer Hellstrand, et al.
BMC Medical Genetics|September 18, 2012
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infectionKarolina Rembeck, Cristina Maglio, Martin Lagging, et al.
HIV Clinical Trials|August 2, 2006
Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trialsAlan R Lifson, Frank S Rhame, Waldo H Belloso, et al.
AIDS (London, England)|December 6, 2005
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyDeenan Pillay, Krishnan Bhaskaran, Suzanne Jurriaans, et al.
Scandinavian Journal of Gastroenterology|September 30, 2015
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experienceJesper Waldenström, Martti Färkkilä, Karolina Rembeck, et al.
The Journal of Infectious Diseases|August 23, 2003
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 TrialUlrik Bak Dragsted, Jan Gerstoft, Court Pedersen, et al.
The Journal of Infectious Diseases|January 22, 2011
Plasma levels of soluble CD14 independently predict mortality in HIV infectionNetanya G Sandler, Handan Wand, Annelys Roque, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2005
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003Bernard Masquelier, Krishnan Bhaskaran, Deenan Pillay, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
BMC Infectious Diseases|April 9, 2014
Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in EthiopiaAlemseged Abdissa, Daniel Yilma, Jannik Fonager, et al.
Plos One|June 2, 2012
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Åsa Alsiö, Karolina Rembeck, Galia Askarieh, et al.
Hepatology (Baltimore, Md.)|February 13, 2014
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3Karolina Rembeck, Jesper Waldenström, Kristoffer Hellstrand, et al.
BMC Medical Genetics|September 18, 2012
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infectionKarolina Rembeck, Cristina Maglio, Martin Lagging, et al.
HIV Clinical Trials|August 2, 2006
Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trialsAlan R Lifson, Frank S Rhame, Waldo H Belloso, et al.
AIDS (London, England)|December 6, 2005
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyDeenan Pillay, Krishnan Bhaskaran, Suzanne Jurriaans, et al.
Scandinavian Journal of Gastroenterology|September 30, 2015
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experienceJesper Waldenström, Martti Färkkilä, Karolina Rembeck, et al.
The Journal of Infectious Diseases|August 23, 2003
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 TrialUlrik Bak Dragsted, Jan Gerstoft, Court Pedersen, et al.
The Journal of Infectious Diseases|January 22, 2011
Plasma levels of soluble CD14 independently predict mortality in HIV infectionNetanya G Sandler, Handan Wand, Annelys Roque, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2005
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003Bernard Masquelier, Krishnan Bhaskaran, Deenan Pillay, et al.
Pageof 18